Asberg side-effect rating scale for antidepressant相关文献:
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L, Glasgow AM, Brallier J, Pietrzak RH, Murrough JW, Charney DS.
Am J Psychiatry. 2021 Feb 1;178(2):193-202. doi: 10.1176/appi.ajp.2020.20050596. Epub 2021 Jan 5.
PMID:33397139
Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial.
Conway CR, Aaronson ST, Sackeim HA, George MS, Zajecka J, Bunker MT, Duffy W, Stedman M, Riva-Posse P, Allen RM, Quevedo J, Berger M, Alva G, Malik MA, Dunner DL, Cichowicz I, Banov M, Manu L, Nahas Z, Macaluso M, Mickey BJ, Sheline Y, Kriedt CL, Lee YL, Gordon C, Shy O, Tran Q, Yates L, Rush AJ.
Brain Stimul. 2025 May-Jun;18(3):676-689. doi: 10.1016/j.brs.2024.12.1191. Epub 2024 Dec 18.
PMID:39706521
A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.
Neuropsychopharmacology. 2019 Jun;44(7):1224-1232. doi: 10.1038/s41386-019-0369-9. Epub 2019 Mar 13.
PMID:30867553
A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD).
Ng CG, Abousheishaa AA, Low SY, Zainal NZ, Thong KS, Awaluddin AB, Loo TH, Yacob SB, Nik Jaafar NR, Abdul Taib NIA, Mohamad Kamal NAB, Ismail F, Zamaniah Wi W.
Asian Pac J Cancer Prev. 2023 Aug 1;24(8):2583-2591. doi: 10.31557/APJCP.2023.24.8.2583.
PMID:37642043
Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, Brutsche NE, Zarate CA Jr.